Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II study of ZS802 injection in severe hemophilia A
ChiCTR2400079656Phase 2Recruiting
- Sponsor
- Institute of Hematology and Blood Diseases Hospital
- Start
- Jan 2024
- Modality
- AAV Vectors → Viral Vectors → Gene Addition/Replacement → Gene Therapies
- Countries
- 1
01
Overview
Phase 2, open-label trial of ZS802 in hemophilia A (3 arms), sponsored by Institute of Hematology and Blood Diseases Hospital. Primary endpoint: Adverse events. Started Jan 2024; status: recruiting.
02
Drugs
ZS802
03
Conditions
hemophilia A
Beyond the preview
Go deeper on ChiCTR2400079656.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400079656.